Update: Orange Book Listing of Drug Delivery Device Patents After In re Lantus, February 2020
April 21, 2020
Update: Orange Book Listing of Drug Delivery Device Patents After In re Lantus, February 20201 Introduction The U.S. Court of Appeals for the First Circuit recently ruled that Sanofi could potentially be held liable for an antitrust violation for improperly listing an insulin delivery device-related patent in the U.S. Food and Drug Administration’s (“FDA”) Orange… Read more »